Lansing, United States
Niowave, Inc., founded in 2005, is a pioneering player in the Manufacturing and Pharmaceutical industries. Based in the United States, the company is committed to "Accelerating the Fight Against Cancer". Niowave stands out as one of the few domestic suppliers of medical and industrial radioisotopes, leveraging a unique superconducting linear accelerator (linac) approach that obviates the need for a nuclear reactor and weapons-grade uranium (HEU).
This cutting-edge technology simplifies operations, reduces licensing costs, and automates small-scale radiochemical processes without requiring nuclear reprocessing facility licenses. Niowave’s production aligns with existing FDA-approved radiopharmaceutical supply chains, effectively streamlining distribution.
Backed by its latest $500.00K grant investment from the Michigan Economic Development Corporation in April 2023, Niowave is well-positioned to fortify its market position in the vital radioisotope supply sector.
